Anastrozole is cost-effective vs tamoxifen as initial adjuvant therapy in early breast cancer: Canadian perspectives on the ATAC completed-treatment analysis

Rocchi, A.; Verma, Shailendra

doi:10.1007/s00520-006-0035-8

Cited by 33 publications

(31 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Therapy with ai has already been subjected to numerous cost-effectiveness analyses from the Canadian perspective [11][12][13][14] . However, many of the analyses used assumptions that the matured clinical data do not support, including the assumption that differences in disease-free survival will translate into improvements in overall survival.…”

Section: Resultsmentioning

confidence: 99%

Economic Evaluation of Hormonal Therapies for Postmenopausal Women with Estrogen Receptor–Positive Early Breast Cancer in Canada

et al. 2015

View full text Add to dashboard Cite

show abstract

Section: Resultsmentioning

confidence: 99%

Economic Evaluation of Hormonal Therapies for Postmenopausal Women with Estrogen Receptor–Positive Early Breast Cancer in Canada

et al. 2015

View full text Add to dashboard Cite

show abstract

“…A second analysis conducted in the United States, on behalf of the ATAC Trialists' Group, concluded that upfront anastrozole is a cost-effective alternative to tamoxifen for the adjuvant treatment of postmenopausal women with estrogen-receptor-positive, early breast cancer 32 . Rochhi and Verma conducted an economic analysis comparing anastrozole and tamoxifen in the adjuvant treatment of hormone-receptor-positive, postmenopausal patients with early breast cancer, using the typical patient from the ATAC trial over a lifetime horizon and the Canadian public healthcare perspective 33 . In that study, resource utilization was drawn from Statistics Canada, supplemented by an expert panel.…”

Section: Discussionmentioning

confidence: 99%

Cost-effectiveness of anastrozole, in comparison with tamoxifen, in the adjuvant treatment of early breast cancer in Brazil

Fonseca

Araújo²,

Saad³

2009

Rev. Assoc. Med. Bras.

View full text Add to dashboard Cite

Summary objectIve. Breast cancer, a leading type of cancer in many developing countries, is the most frequent non-cutaneous tumor in Brazil. Hormone therapy is the standard of care in the adjuvant treatment of early-stage, hormone-receptor-positive disease, and both tamoxifen and third-generation aromatase inhibitors are options in postmenopausal women. The comparative cost-effectiveness of different treatment strategies is of considerable interest in societies facing limited resources. Methods.In an attempt to compare cost-effectiveness of upfront treatment with tamoxifen or anastrozole, the medical and economic results in a hypothetical cohort of 64-year-old postmenopausal women, was analyzed considering the Brazilian healthcare system in 2005, the primary perspective of the private sector, and a lifetime horizon. Data from the ATAC Trial, Markov modeling, a modified Delphi panel, and microcosting (in Brazilian R$) were used to estimate costs and effectiveness of the two upfront strategies. results. The model estimated a gain of 0.55 discounted life-years for patients receiving anastrozole, relative to those treated with tamoxifen. With an incremental cost of R$ 15,141.15, the model estimated that the cost-effectiveness of anastrozole, in relation to tamoxifen, was R$ 27,326.80. Monte Carlo simulations showed that approximately 50% of the cases fell below the threshold of R$ 29,229.00 per life-year gained, which is recommended by the World Health Organization for Brazil. conclusIon. It was concluded that upfront anastrozole is a cost-effective option compared with tamoxifen in the adjuvant treatment of postmenopausal women with hormone-receptor-positive early breast cancer.

show abstract

“…"Routine care" included physician visits; blood work; thyroid-stimulating hormone, triiodothyronine, amylase, and lipase tests; and computed tomography and bone scans. Costs of disease progression and death were derived from a previously published study of the cost-effectiveness of breast cancer treatment 42 , assuming that such costs would be independent of cancer type.…”

Section: Costsmentioning

confidence: 99%

Cost-Effectiveness of Pazopanib Compared with Sunitinib in Metastatic Renal Cell Carcinoma in Canada

et al. 2016

View full text Add to dashboard Cite

show abstract

Anastrozole is cost-effective vs tamoxifen as initial adjuvant therapy in early breast cancer: Canadian perspectives on the ATAC completed-treatment analysis

Abstract: Compared to tamoxifen, anastrozole therapy is effective and cost-effective as initial adjuvant therapy in post-menopausal, HR+ early breast cancer patients.

Cited by 33 publications

References 38 publications

Economic Evaluation of Hormonal Therapies for Postmenopausal Women with Estrogen Receptor–Positive Early Breast Cancer in Canada

Economic Evaluation of Hormonal Therapies for Postmenopausal Women with Estrogen Receptor–Positive Early Breast Cancer in Canada

Cost-effectiveness of anastrozole, in comparison with tamoxifen, in the adjuvant treatment of early breast cancer in Brazil

Cost-Effectiveness of Pazopanib Compared with Sunitinib in Metastatic Renal Cell Carcinoma in Canada

Contact Info

Product

Resources

About